Joanie Pfahl and Jennifer Sutton explain the importance of informing and educating the patient, and why it is essential for nurses to have up-to-date knowledge.

Watch the video and download the slides


The GUIDE Communication Framework: Strengthening shared decision-making between nmCRPC patients and the healthcare team

This is the second in a series of three newsletters explaining the GUIDE Communication Framework, a simple 5-step approach to optimise the role of the nurse in strengthening shared decision-making between nmCRPC patients and their healthcare team.

GUIDE’s five letters each represent a crucial step in your conversations with patients with prostate cancer.

  • Gain insight into goals of treatment and care
  • Understand gaps in the patient's knowledge
  • Inform and educate
  • Direct to additional support
  • Empower the patient

Joanie Pfahl and Jennifer Sutton cover step 3 of the GUIDE Communication Framework and explain the importance of Informing and educating the patient, and why it is essential for nurses to have up-to-date knowledge about the disease and common symptoms, key studies relating to nmCRPC, treatment aims and options, potential side effects and proactive management as addressing patients’ knowledge gaps in the right way is critical in managing their treatment successfully.

In the first newsletter, Veerle Lamotte covered steps 1 and 2 of the GUIDE framework and explained why it’s important to Gain insight into the goals of treatment and care as a first step in supporting your patients along the agreed treatment journey and how to Understand the gaps in the patient’s knowledge, allowing you to prioritise where you focus when it comes to informing and educating the patient.

In the third newsletter, Jason Alcorn explains how to Direct the patient and the carer to additional support and the importance of Empowering the patient, making them feel they can actively participate in the shared decision-making and treatment process, and why these steps are an important part of a successful treatment journey.

Hello, my name is Joanie Pfahl. I am a resident nurse with the Atlantic Urology Clinics in Myrtle Beach, South Carolina. I’m going to talk about: Strengthening shared decision making between non-metastatic castrate-resistant prostate cancer patients and the healthcare team, and how we can use the GUIDE communication framework to support discussions with our patients.

Inform and educate the patient about treatment options

We will be focusing on step 3 of the framework, which includes how and what are the best ways to inform and educate the patient with regards to their treatment options. Since 2018, the treatment landscape for non-metastatic CRPC has changed with the approval of three next-generation oral androgen receptor inhibitors. They are apalutamide: SPARTAN trial, enzalutamide: PROSPER trial, and darolutamide with ARAMIS trial.

With the availability of the new AR target option, oncology nurses play a crucial role in the decision-making process; with educating, supporting, and to help the patients manage their prostate cancer. While ensuring they receive the most appropriate information to help their treatment decisions. It is essential that we educate and inform patients regarding their treatment aims for non-metastatic CRPC, and they are: prolong survival, delay metastasis, alleviation of tumour-related symptoms, balancing potential benefits against likely treatment toxicity, and maintaining quality of life.

While no head-to-head comparison of apalutamide, enzalutamide and darolutamide have been conducted to date, all three have demonstrated comparable efficacy and maintained quality of life in the SPARTAN, PROSPER and ARAMIS trials, but they have differing AE profiles. So why is the GUIDE communication framework needed?

Shared decision-making

Nurses are seen as the go-to person for their patients with non-metastatic CRPC, and therefore must empower patients with guidance and support, throughout their treatment journey, ensure patients are provided with the right information with their treatment decisions and to help fill in the gaps with their patient’s knowledge, and to be an active member of the healthcare team, in delivering shared decision-making, so they can provide patients with the greatest chance of success and meaningful, prolonged length of survival; to see their new grandchild, to attend a wedding, to attend a graduation or to plan a vacation.

Please go to gunursesconnect.cor2ed.com to take an in-depth look at the prepared slides and thank you for listening to the GU NURSES CONNECT.

Joanie Pfahl is a registered nurse working as the outpatient infusion nurse at Atlantic Urology Clinics (AUC) in Myrtle Beach, SC.  She received her Associate Degree in Nursing from Mount Aloysius College in Cresson, PA. Joanie has over 36 years of experience as a registered nurse in multiple areas including the intensive care unit, medical surgical unit, emergency room, pediatrics, and oncology.  Since November 2015, she has been administering chemotherapy and immunotherapy infusions to patients with genitourinary malignancies, which includes renal cell carcinoma, urothelial cancer, and advanced prostate cancer.  The unique position as the infusion nurse at AUC has been constantly evolving with the new advances of immunotherapy treatments.  Joanie has been adapting to the new treatment landscape by developing new policies and procedures for AUC, educating patients and their families on their treatments, managing adverse events, and coordinating patient care between multiple disciplinary areas of oncology. Joanie is a member of the Oncology Nursing Society and the Society of Urologic Nurses and Associates. As a member of the rapid response team at AUC, she has her Advanced Cardiac Life Support certification. Joanie has also served on multiple advisory boards for renal cell carcinoma and urothelial cancer.

Jennifer Sutton is a registered nurse and the Director of Nursing and Administration at Carolina Urologic Research Center in Myrtle Beach, SC.  After receiving her Bachelor of Science degree in Exercise Science with a minor in Chemistry from the University of South Carolina, she earned her Associate Degree in Nursing from Horry Georgetown Technical College. Jennifer is a member of the Society of Urologic Nurses and Associates, the Oncology Nursing Society, and the Association of Clinical Research Professionals (ACRP).   She is an ACRP-certified Clinical Research Coordinator and has more than 11 years of experience managing and administering cutting edge therapies to patients with genitourinary malignancies and other urologic disorders.  Additionally, she manages a team of research professionals that coordinate phase I-IV clinical trials in all areas of urology.  In recent years, she has served on multiple prostate cancer and bladder cancer advisory boards and has published articles on emerging prostate cancer treatments and effective structuring and management of a clinical research center. 

Jennifer Sutton has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Bayer, Janssen, Merck, Myovant and SeSen Bio. 

Programme summary
Share this programme
This educational programme is supported by an Independent Educational Grant from Bayer
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from Bayer
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
GU NURSES CONNECT

GU NURSES CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from AstraZeneca, Bayer, and Eisai Europe Limited.

Meet the experts Independent IME approved

Other programmes of interest

eks
EKS / On-demand webinar
Oncology 
Multiple Myeloma: Is it time to rethink how we sequence treatments?

On-demand materials from an Experts Knowledge Share event

Experts
Prof. Karthik Ramasamy, Dr Joshua Richter, Dr Faisal Basheer, Dr Andrew Charlton
  • download Downloadable
    Resources
  • clock 80 MIN
  • calendar Mar 2026

This programme has been sponsored by Menarini Stemline and is intended for HCPs in the UK only    MAT-GB-SEL-00774
conference-update Conference update

Episode

2

of 2

episode
Oncology Rare diseases Endocrinology 
Actualités du Congrès l’ENETS 2026

Points de vue d’experts sur les dernières données concernant le cancer neuroendocrinien

Experts
Prof. Louis de Mestier, Prof. Timon Vandamme, Dr Alice Durand
  • clock 5 MIN
  • calendar Mar 2026
  • Non-accredited Independent Medical Education

Cette vidéo est soutenue par une subvention indépendante à visée éducative d’Ipsen.  Les contenus publiés sur ce site internet sont sous la responsabilité de leurs auteurs. Certaines données scientifiques publiées sur ce site sont susceptibles de ne pas être validées par la commission d’Autorisation de Mise sur le Marché, et ne doivent pas être mises en pratique. Elles doivent être lues et comprises avec le plus grand discernement et sont données dans leur cadre de la diffusion de l’information sur l’état actuel de la recherche auprès de la communauté scientifique internationale  
conference-update Conference update

Episode

1

of 2

episode
Oncology Rare diseases Endocrinology 
Update from ENETS 2026

Experts share their views on latest data in neuroendocrine cancer

Experts
Prof. Louis de Mestier, Prof. Timon Vandamme, Dr Alice Durand
  • clock 5 MIN
  • calendar Mar 2026
  • Non-accredited Independent Medical Education

This educational programme is supported by an Independent Educational Grant from Ipsen. The content published on this website is under the responsibility of its authors. Some scientific data published on this website may not have been validated by the relevant Marketing Authorisation Committees and should not be put into practice. It should be read and understood with the utmost discernment and is provided for the purpose of disseminating information on the current state of research to the international scientific community.
conference-update Conference update
Oncology 
Update from ESGO 2026 – PYNNACLE Phase 2 study: Interim results from the ovarian cancer cohort

Clinical insights and expert discussion

Experts
Prof. Domenica Lorusso, Prof. Jean-Sebastien Frenel
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Mar 2026

This programme has been sponsored by PMV Pharma and is intended for HCPs only.
publication Scientific Publication
Oncology 
ADCs in HER2+ metastatic breast cancer and management of adverse events

Consensus-based guidance for clinicians and patients

Experts
Prof. Javier Cortés, Prof. Giuseppe Curigliano, Prof. Shaheenah Dawood, Dr Grażyna Suchodolska, Dr Sara Tolaney, Carla Whitbread
Endorsed by
EONS - European Oncology Nursing Society Europa Donna
  • download Downloadable
    Resources
  • clock 20 MIN
  • calendar Feb 2026
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from AstraZeneca